May 10, 2024
X4 Pharmaceuticals has gained approval for its first product, XOLREMDI (mavorixafor), marking its entrance into the commercial rare disease market. The FDA approved mavorixafor on April 29, 2024, specifically for patients aged 12 and above diagnosed with WHIM syndrome (characterized by warts, hypogammaglobulinemia,...
Read More...
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper